Literature DB >> 14962414

Photodynamic therapy for age-related macular degeneration in a clinical setting: visual results and angiographic patterns.

Ruth Axer-Siegel1, Rita Ehrlich, Yuval Yassur, Irit Rosenblatt, Michal Kramer, Ethan Priel, Yoav Benjamini, Dov Weinberger.   

Abstract

PURPOSE: To evaluate the visual outcome of patients with subfoveal choroidal neovascularization due to age-related macular degeneration, who received photodynamic therapy (PTD) in a clinical setting and to identify potential predictive visual and angiographic factors.
DESIGN: Interventional case series.
METHODS: The study included 74 patients with subfoveal choroidal neovascularization who underwent PDT from January 2000 to March 2001 and completed at least 1 year follow-up. All patients received verteporfin PDT and were followed clinically, with fluorescein angiography (74 eyes), and with indocyanine green angiography (65 eyes). A review of the medical records and angiograms was performed.
RESULTS: Mean follow-up was 15.6 months. Patients received a mean of 3.4 treatments per year. Sixty-six percent lost less than 3 Snellen lines of visual acuity. Three patients (4%) experienced profound visual acuity loss to finger counting. Final visual acuity was positively correlated with lesion size and visual acuity at presentation. Visual outcome was worse in the presence of cystoid macular edema. On indocyanine green angiography, a round hypofluorescent spot was seen at the site of the PDT, with maintenance of medium and large choroidal vessels.
CONCLUSION: Smaller lesion size and better visual acuity at presentation were good predictive signs, whereas cystoid macular edema was found to be a poor prognostic sign for visual outcome following PDT.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14962414     DOI: 10.1016/j.ajo.2003.08.009

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  10 in total

1.  Photodynamic therapy with verteporfin for choroidal neovascularisations in clinical routine outside the TAP study. One- and two-year results including juxtafoveal and extrafoveal CNV.

Authors:  Joachim Wachtlin; Andrea Stroux; Andreas Wehner; Heinrich Heimann; Michael H Foerster
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-12-11       Impact factor: 3.117

2.  One-year outcomes after photodynamic therapy in patients with age-related macular degeneration with poor baseline visual acuity.

Authors:  Michael J Potter; Shelagh M Szabo
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-12-08       Impact factor: 3.117

3.  Impact of lesion size on photodynamic therapy with verteporfin of predominantly classic lesions in age related macular degeneration.

Authors:  L Arias; O Pujol; J Berniell; M Rubio; G Roca; L Castillo; E Acebes
Journal:  Br J Ophthalmol       Date:  2005-03       Impact factor: 4.638

4.  Photodynamic therapy for polypoidal choroidal vasculopathy: baseline perimetric results and visual outcomes.

Authors:  Mitsuhiro Imasawa; Toyoaki Tsumura; Arata Sekine; Toyohiko Kikuchi; Hiroyuki Iijima
Journal:  Jpn J Ophthalmol       Date:  2009-12-18       Impact factor: 2.447

5.  Verteporfin therapy for neovascular age-related macular degeneration in Indian eyes.

Authors:  Nazimul Hussain; Taraprasad Das; Rohit Khanna; Kallukuri Sumasri; Lakshmana Samudram Mohan Ram
Journal:  Jpn J Ophthalmol       Date:  2006-12-18       Impact factor: 2.447

6.  [Photodynamic therapy of AMD for the first (better sight) and the second (worse sight) eyes].

Authors:  A C Marti; F K P Sutter; D Barthelmes; J C Fleischhauer; M M Kurz-Levin; M M Bosch; H Helbig
Journal:  Ophthalmologe       Date:  2007-02       Impact factor: 1.059

7.  Multifocal electroretinography as a predictor of maintenance of vision after photodynamic therapy for neovascular age-related macular degeneration.

Authors:  Alison M Mackay; Malcolm C Brown; Ian Grierson; Simon P Harding
Journal:  Doc Ophthalmol       Date:  2007-09-21       Impact factor: 2.379

Review 8.  Targeted radiotherapy with gold nanoparticles: current status and future perspectives.

Authors:  Wilfred Ngwa; Rajiv Kumar; Srinivas Sridhar; Houari Korideck; Piotr Zygmanski; Robert A Cormack; Ross Berbeco; G Mike Makrigiorgos
Journal:  Nanomedicine (Lond)       Date:  2014-05       Impact factor: 5.307

9.  Impact of methylenetetrahydrofolate reductase C677T polymorphism on the efficacy of photodynamic therapy in patients with neovascular age-related macular degeneration.

Authors:  Francesco Parmeggiani; Carla Enrica Gallenga; Ciro Costagliola; Francesco Semeraro; Mario R Romano; Roberto Dell'Omo; Andrea Russo; Katia De Nadai; Donato Gemmati; Sergio D'Angelo; Elena Bolletta; Francesco Saverio Sorrentino
Journal:  Sci Rep       Date:  2019-02-22       Impact factor: 4.379

10.  Effect of Factor XIII-A G185T Polymorphism on Visual Prognosis after Photodynamic Therapy for Neovascular Macular Degeneration.

Authors:  Francesco Parmeggiani; Ciro Costagliola; Francesco Semeraro; Mario R Romano; Michele Rinaldi; Carla Enrica Gallenga; Maria Luisa Serino; Carlo Incorvaia; Sergio D'Angelo; Katia De Nadai; Roberto Dell'Omo; Andrea Russo; Donato Gemmati; Paolo Perri
Journal:  Int J Mol Sci       Date:  2015-08-20       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.